CTLA4 and cancer: The characterization of immune infiltrates—such as TAMs, T lymphocytes, and myeloid-derived suppressor cells—as well as immune evasion mechanisms involving checkpoint molecules such as PD-1, PD-L1, and CTLA-4, is beginning to transform our approach to cancer therapy in animals.